Being Black and running an NCI-designated cancer center at a time of a worldwide pandemic, an ugly election, and a racial reckoning in a Southern town puts you in a position to make profound observations.
Twenty-five years ago, The Cancer Letter missed a big story.
In his previous job, in North Carolina, Edward S. Kim helped build a cancer program where there was none.
Sean Khozin, a data science expert and formerly a senior medical officer at FDA, has been tapped to lead CancerLinQ—the American Society of Clinical Oncology's multimillion-dollar big data initiative designed to generate real-world evidence from patient records.
“I think cell therapy is going to continue to be a very, very important treatment modality for cancer, and we would like to see the Tampa Bay area become the cell therapy capital of the universe,” Hwu, the new president and CEO of H. Lee Moffitt Cancer Center, said to The Cancer Letter.
Julie R. Gralow, an expert in breast cancer, clinical trials and global health, was named chief medical officer of the American Society of Clinical Oncology.
As he watches COVID-19 numbers climb in New Jersey, Steven K. Libutti reviews all the things he had learned last spring, when the pandemic first slammed the state.
Will an oncologist of the not-so-distant future be able to pull up an image of a tumor biopsy slide on a screen and—without having to order a biomarker test—see the molecular characteristics of the cancer?
Rachelle Monteau first learned about Memorial Sloan Kettering Cancer Center through her father, who worked as a physician assistant, and who served on medical mission trips to Haiti, his home country.
